Related Experiment Videos
Insulin-like growth factor-I: clinical studies
P E Vos1, H P Koppeschaar, W R de Vries
1Department of Neurology, University Hospital Utrecht, The Netherlands.
Drugs of Today (Barcelona, Spain : 1998)
|April 20, 2004
Summary
Insulin-like growth factor-I (IGF-I) is a key hormone with diverse roles. Recombinant human IGF-I (rhIGF-I) shows promise for treating neurological conditions, despite potential side effects.
Area of Science:
- Endocrinology
- Cell Biology
- Neuroscience
Background:
- Insulin-like growth factor-I (IGF-I) exhibits endocrine, autocrine, and paracrine functions.
- IGF-I receptors are widely distributed, particularly on mesenchymal cells like fibroblasts, chondrocytes, and osteoblasts.
- IGF-I plays roles in bone growth, metabolic disorders, and diseases including cancer and thyroid conditions.
Purpose of the Study:
- To review the multifaceted roles of IGF-I.
- To highlight the therapeutic potential of recombinant human IGF-I (rhIGF-I) in various diseases.
- To discuss the emerging role of IGF-I as a neurotrophic factor.
Main Methods:
- Review of existing literature on IGF-I.
- Analysis of clinical trial data for rhIGF-I in neurological diseases.
- Summary of known physiological and pathological functions of IGF-I.
Main Results:
- rhIGF-I is effective in treating Growth Hormone (GH)-resistant Laron dwarfism and severe insulin resistance.
- Phase II trials indicate rhIGF-I efficacy in neurological conditions like traumatic brain injury, myotonic dystrophy, and amyotrophic lateral sclerosis.
- Potential side effects of rhIGF-I treatment include increased heart rate, edema, and hypertension.
Conclusions:
- IGF-I is a critical factor with broad physiological implications.
- rhIGF-I represents a significant therapeutic advancement for specific endocrine and neurological disorders.
- Further research into IGF-I's neurotrophic properties and management of its side effects is warranted.